roflumilast sold trade name daxas among others drug acts selective longacting inhibitor enzyme antiinflammatory effects used orally administered drug treatment inflammatory conditions lungs chronic obstructive pulmonary disease june approved european union severe copd associated chronic february gained fda approval united states reducing copd available generic roflumilast indicated treatment severe chronic obstructive pulmonary disease treatment plaque used prevention exacerbations lung attacks severe chronic obstructive pulmonary disease common incidence adverse effects httpsenwikipediaorgwikiroflumilast